Compare · CNTG vs ELV
CNTG vs ELV
Side-by-side comparison of Centogene N.V. (CNTG) and Elevance Health Inc. (ELV): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CNTG and ELV operate in Medical Specialities (Health Care), so they compete in similar markets.
- ELV is the larger of the two at $87.86B, about 941.9x CNTG ($93.3M).
- ELV has hit the wire 4 times in the past 4 weeks while CNTG has been quiet.
- ELV has more recent analyst coverage (23 ratings vs 1 for CNTG).
- Company
- Centogene N.V.
- Elevance Health Inc.
- Price
- $0.56+86.47%
- $404.50-4.68%
- Market cap
- $93.3M
- $87.86B
- 1M return
- -
- +5.98%
- 1Y return
- -
- +6.15%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NYSE
- IPO
- 2019
- News (4w)
- 0
- 4
- Recent ratings
- 1
- 23
Centogene N.V.
Centogene N.V., together with its subsidiaries, focuses on rare diseases that transforms real-world clinical and genetic, or other data into actionable information for patients, physicians, and pharmaceutical companies worldwide. The company develops rare disease platform, a data repository, which includes epidemiologic, phenotypic, and heterogenetic data that enhances methods for identifying and monitoring rare hereditary diseases and provide solutions that accelerate the development of orphan drugs. It provides various services, including target discovery, early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring; and genetic sequencing and diagnostics services to physicians, laboratories, or hospitals directly or through distributors. The company also offers COVID-19 testing solutions, including RT-PCR and antigen testing services. It has a strategic collaboration with Shire International GmbH and Pfizer Inc.; a collaboration agreement with Dr. Bauer Laboratoriums GmbH, Rostock by providing the medical laboratory services to perform its COVID-19 testing business activities; and a license agreement with Fraport AG to operate a test center for COVID-19 testing/diagnostics at Frankfurt Airport, Germany. Centogene N.V. was founded in 2006 and is headquartered in Rostock, Germany.
Elevance Health Inc.
Elevance Health Inc. operates as a health benefits company. It supports consumers, families, and communities across the entire care journey connecting to the care, support, and resources to lead healthier lives. It serves approximately 118 million people through a portfolio of medical, digital, pharmacy, behavioral, clinical, and care solutions. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health Inc. in June 2022. Elevance Health Inc. was founded in 1944 and is headquartered in Indianapolis, Indiana.
Latest CNTG
- CENTOGENE Closes Strategic Transaction with Private Equity Group Charme Capital Partners
- CENTOGENE Announces Voting Results of Extraordinary General Meeting
- CENTOGENE Signs Strategic Transaction With Private Equity Group Charme Capital Partners
- CENTOGENE Data on Novel Genetic Risk Factor for Parkinson's Disease in The Lancet Neurology
- SEC Form 6-K filed by Centogene N.V.
- SEC Form 6-K filed by Centogene N.V.
- CENTOGENE Receives Delisting Notice From Nasdaq
- SEC Form 6-K filed by Centogene N.V.
- CENTOGENE Publication in Brain Journal Reveals 15% of Parkinson's Disease Cases Are Linked to Genetic Factors
- Centogene shares are trading higher after the company signed a Memorandum of Understanding with C-Path for collaboration in lysosomal disease research and drug development.
Latest ELV
- Elevance Health Inc. filed SEC Form 8-K: Regulation FD Disclosure
- Elevance Health Expands Access to Digital Tools, Helping Bridge the Healthcare Digital Divide
- CAO & Controller Penczek Ronald W exercised 1,531 shares at a strike of $294.30 and sold $617,192 worth of shares (1,531 units at $403.13) (SEC Form 4)
- Elevance Health upgraded by Deutsche Bank with a new price target
- Director Schulman Amy W was granted 563 shares, increasing direct ownership by 258% to 781 units (SEC Form 4)
- Director Schneider Ryan M. was granted 563 shares, increasing direct ownership by 9% to 7,163 units (SEC Form 4)
- Director Peru Ramiro G was granted 563 shares, increasing direct ownership by 6% to 9,908 units (SEC Form 4)
- Director Neri Antonio F was granted 563 shares, increasing direct ownership by 11% to 5,488 units (SEC Form 4)
- Director Jallal Bahija was granted 563 shares, increasing direct ownership by 12% to 5,351 units (SEC Form 4)
- Director Hay Lewis Iii was granted 563 shares, increasing direct ownership by 5% to 12,070 units (SEC Form 4)